3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
6
Nivolumab
3
Gemcitabine
3
Cisplatin
3
Carboplatin
3
brigimadlin
2
Ramucirumab
2
Fluorouracil
2
Docetaxel
2
Cetuximab
2
tucatinib
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
regorafenib
1
pertuzumab
1
milademetan
1
larotrectinib
1
futibatinib
1
durvalumab
1
cemiplimab
1
adagrasib
1
Trastuzumab
1
TAS-116
1
Ritonavir
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Omacor
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
AZD9833
×
Thoracic
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled